Authors : B.Cherkaoui; I. Belrhali; S. Ibrahimi; O. Caliez; I. Cojean Zelek; H.Mrabti; I. El Ghissassi; H. Errihani

Volume/Issue : Volume 9 - 2024, Issue 8 - August

Google Scholar : https://tinyurl.com/4yc4fa7b

Scribd : https://tinyurl.com/35mcw9fh

DOI : https://doi.org/10.38124/ijisrt/IJISRT24AUG399

Abstract : Introduction Colorectal cancer represents 1,271 new cases per year in Morocco, However, over the last 30 years we have witnessed a significant increase in the overall survival of metastatic patients due to the arrival of new molecules.  Case Presentation We report the case of a 51 years old african female patient diagnosed for a moderately differentiated adenocarcinoma of the rectosigmoid junction MSS, wild RAS/BRAF, treated with colorectal protection and lymph node dissection, followed by 6 cycles of fulfol- cisplatin as an adjuvant. the follow up revealed the appearance of hepatic masses. The liver biopsy was performed showing a secondary localization of an adenocarcinoma of digestive origin. The patient received four lines of the chemotherapy, anti-EGFR antibodies and immunotherapy following the guidelines. However, since no KRAS NRAS BRAF mutation was detected at the DNA level circulating tumor, no rechallenging of the anti- EGFR was possible. The hepatic progression continued with appearance of pulmonary lesions, the decision was made for a palliative care.  Conclusion Our case highlights that due to the emergence of new effective molecules currently available, associated with a dedicated onco-surgical approach, more patients will be able to benefit from prolonged survival that did not seem achievable at the time of diagnosis.

Keywords : Biomarkers, Metastatic Colorectal Cancer, SystemicTreatment, Overall Survival.

References :

1. Mohamed Said Belhamidi et al. Profil épidémiologique et anatomopathologique du cancer colorectal: à propos de 36 cas. Pan African Medical Journal.2018; 30: 159.[doi: 10.11604/pamj.2018.30.159.15061]
2. Chibaudel B, Dourthe LM, Andre T, Henriques J, Bourgeois V, Etienne PL, et al. STRATEGIC-1: Multi-line therapy trial in unresectable wild- type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR- PRODIGE randomized open-label phase III study. J Clin Oncol 40, 2022 (suppl 16; abstr 3504).
3. Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, et al. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO, J Clin Oncol. 40, no. 25 (September 01, 2022) 2878-2888.
4. Tzu-Fei-Wang and Albert Craig Lockhart [email protected] View all authors and affiliations, Aflibercept in the Treatment of Metastatic Colorectal Cancer https://doi.org/10.4137/CMO.S7432
5. Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A BEBYP Study Investigators. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol . 2015;26:724–730. [PubMed] [Google Scholar]
6. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso- Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S ML18147 Chercheurs de l’étude. Poursuite du bevacizumab après une première progression du cancer colorectal métastatique (ML18147) : un essai randomisé de phase 3. Lancette Oncol. 2013 ; 14 : 29-37. [ PubMed ] [ Google Scholar ]
7. Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, Bartolini A, Fenocchio E, Amatu A, Manca P, Bergamo F, Tosi F, Mauri G, Ambrosini M, Daniel F, Torri V, Vanzulli A, Regge D, Cappello G, Marchiò C, Berrino E, Sapino A, Marsoni S, Siena S, Bardelli A. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28:1612–1618. [PMC free article] [PubMed] [Google Scholar]
8. Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med 2023 May 4;388(18):1657-1667.